Information Provided By: 
Fly News Breaks for February 13, 2019
CLVS
Feb 13, 2019 | 07:08 EDT
H.C. Wainwright analyst Edward White started Clovis Oncology with a Buy rating and $40 price target. Investors are missing the potential opportunity that the PARP market holds in ovarian cancer and other indications, White tells investors in a research note. While penetration of the PARP market has been slow, investors are not giving Clovis enough credit for the potential size of the market, says the analyst. He believes the size of the monotherapy ovarian cancer PARP market "has plenty of room to expand."
News For CLVS From the Last 2 Days
There are no results for your query CLVS
